STUDY OF TETRATHIOMOLYBDATE (TM) AS A DECOPPERING AND ANTIANGIOGENESIS OF CANCER

由于细胞减灭化疗的累积毒性和耐药性，转移性实体瘤患者的治疗选择通常非常有限。 维持或减小转移性肿瘤大小的新方法是抑制新血管生长到肿瘤床或血管生成中。 铜已被证明是动物血管生成的必需品。我们试图确定铜的减少是否会导致实体瘤的缩小或减缓其生长。 已知最有效的铜抑制剂是四硫代钼酸盐（TM），在UM开发用于治疗组织中铜含量极高的威尔逊病患者。 尽管TM已安全地用于患有威尔逊病的人，但其在转移性癌症患者中的毒性特征尚不清楚。 我们提出了一项在已经用尽其他治疗方案的转移性实体瘤患者中进行TM的I期研究。

Patients with metastatic solid tumors often have very limited treatment options due to cumulative toxicity of cytoreductive chemotherapy and drug resistance. A new approach to the maintenance or reduction in size of metastatic tumors is inhibition of new blood vessel growth into the tumor bed or angiogenesis. Copper has been shown to be a requirement for angiogenesis in animals. We seek to determine whether a decrease in copper causes shrinkage or slows growth of solid tumors. The most potent inhibitor of copper known is Tetrathiomolybdate (TM), developed at the UM for the treatment of patients with Wilson's disease who suffer from extremely high levels of copper in tissues. Whereas TM has been safely administered to humans with Wilson's disease, its toxicity profile in patients with metastatic cancer is not known. We propose a Phase I study of TM in patients with metastatic solid tumors who have exhausted other treatment options.